Key Takeaways

  • MacuMira has received CE Mark certification under EU MDR for its noninvasive retinal microcurrent stimulation treatment for dry AMD

  • A randomized, sham-controlled trial demonstrated a 10.4-letter greater improvement in visual acuity and a 0.25-log-unit greater improvement in contrast sensitivity compared with sham treatment at 30 weeks

  • The device has been used in more than 300 clinics, with over 40,000 treatments delivered

MacuMira Medical Devices has received CE Mark certification under the European Union Medical Device Regulation (MDR 2017/745) for its retinal microcurrent stimulation device for the treatment of dry age-related macular degeneration (AMD).

MacuMira is a noninvasive, in-clinic treatment that delivers low-level electrical microcurrent through closed eyelids during 32-minute sessions. The therapy is believed to stimulate cellular metabolic processes in photoreceptors and the retinal pigment epithelium. Treatment involves an initial series of sessions followed by maintenance therapy.

Clinical evidence supporting the device includes a randomized, sham-controlled trial published in the International Journal of Retina and Vitreous in 2023. Patients receiving MacuMira gained an average of 10.4 more letters of visual acuity than sham-treated patients at 30 weeks, with a 0.25-log-unit greater improvement in contrast sensitivity.1

An unpublished retrospective analysis of 251 patients across 24 clinics, encompassing more than 1,700 treatments, found an average visual acuity gain of 6.4 letters during the first 2 weeks. Visual acuity remained within 2.4 letters of peak improvement through 15 months.2

According to the company, MacuMira has been used in more than 300 clinics, with over 40,000 treatments administered to date.

“Achieving CE Mark certification is a significant milestone for MacuMira and an important step in expanding access to our technology,” said Matt Van de Ven, CEO of MacuMira Medical Devices Inc. “For too long, patients with dry AMD have had limited treatment options. With a growing body of clinical evidence and extensive real-world experience, we are excited to bring a new approach to vision improvement to patients and clinicians across Europe.”

The certification expands the device's availability to Europe, joining Canada, Australia, and New Zealand, where the treatment is already available.

References

1. Parkinson KM, et al. International Journal of Retina and Vitreous. 2023;9:36.

2. MacuMira Retrospective Real-world Outcome Analysis. Internal data, unpublished.